Introduction
Signal transducer and activator of transcription (Stat) proteins are a family of latent transcription factors activated by a number of cytokines and growth factors including epidermal growth factors (EGF), interleukin-6 (IL-6) and oncostatin M (OsM). In addition, reports by several groups have shown that Stat molecules are constitutively activated in a number of cancers and cancer-derived cell lines (Catlett-Falcone et al., 1999; Garcia et al., 1997; Grandis et al., 2000; Ni et al., 2000; Nielsen, 1999; Weber-Nordt et al., 1996) .
Several studies have implicated that the activation of Stat3a may be important in aberrant proliferation, and it has been shown to be required for v-Src-mediated transformation of ®broblasts (Bromberg, 1998; Turkson, 1998) . The two proteins have also been shown to interact directly (Cao et al., 1996) . Stat3 is required for the induction of the c-myc gene (Kiuchi et al., 1999) , and in other studies constitutively activated Stat3 is responsible for elevated levels of bcl-XL , a molecule involved in preventing apoptosis (Catlett-Falcone et al., 1999) .
The activation of Stat proteins requires the phosphorylation on a single tyrosine residue, an event that is essential for dimerization and subsequent DNA binding. Dimerization of Stats involves the reciprocal interaction between the phosphorylated tyrosine residue of one Stat and the src homology-2 (SH2) domain of its dimerization partner. This post-translational event can also serve as a molecular tag since a number of antibodies that recognize this phosphotyrosine are commercially available.
Glioblastoma multiforme (GBM) is a highly malignant form of brain tumor. One of the genetic hallmarks of GBM is an elevated level of the EGF receptor due to gene ampli®cation (Libermann et al., 1984 (Libermann et al., , 1985 Filmus et al., 1985; Schlegel et al., 1994) . Another common feature of these tumors is a rearrangement of the receptor gene that results in an in-frame deletion of exons 2 ± 7 (Batra et al., 1995; Schwechheimer, 1995; Wong, 1992) . The receptor molecule encoded by this gene is unable to bind ligand yet is constitutively activated (Batra et al., 1995) . Stat3 is a known downstream target of EGF (David et al., 1996) signaling and is recruited to the activated receptor via association of Stat3 to phosphorylated tyrosine residues in the cytoplasmic domain of the receptor.
In addition to the tyrosine kinase EGFR, other TK's known to activate Stat3 may be important in activating signaling pathways relevant to gliomagenesis. These proteins include Src (Yu et al., 1995) and the endothelial receptor vascular endothelial growth factor receptor-2 (VEGFR-2) (Korpelainen et al., 1999) . A transgenic mouse model in which the v-src gene was under control of the glial ®brillary acidic protein (GFAP) formed tumors that morphologically and molecularly resembled human GBM (Theurillat et al., 1999) . In another study dissecting the molecular pathway involved in VEGF signaling, enforced expression of VEGFR-2 resulted in ligand-independent activation of Stat3 (Korpelainen et al., 1999) . Surprisingly, unlike Stat activation by the receptor tyrosine kinases PDGFR and EGFR, which activate both Stat1 and Stat3, the expression of this endothelial RTK did not activate Stat1.
Despite the established connection between EGFR and Stat activation, in a previous study we were unable to detect any appreciable constitutively activated Stat3a in any of the eight GBM lines tested, although protein was readily activated by a number of cytokines (Schaefer et al., 2000a) . Since tumor-derived cell lines established in culture often lose properties associated with the primary tumor, we turned our studies to the analysis of the activation status of Stat3a in GBM tumor tissue. In this study, we demonstrate that Stat3a is constitutively activated in both low and high-grade brain tumors as assessed by electrophoretic mobility shift assays and immunoblot analysis with an antibody to the tyrosine-705 phosphorylated form of the molecule. We also present data in which the activated Stat3a was found to localize predominantly to the tumor endothelial cells. We also demonstrate that expression of VEGFR-2 leads to the activation Stat3a in cells that express both proteins providing a potential mechanism for the activated Stat3a observed in brain tumor tissue. Finally, we show that activated Stat3a can dramatically increase the transcription from the VEGF promoter implicating the involvement of Stat3 signaling in tumor angiogenesis.
Results
Human glioma and medulloblastoma tissue specimens contain constitutively activated Stat3a molecules Nuclear extracts were prepared from residual glioma tumor samples and used in electrophoretic mobility shift assay experiments (EMSA), a sensitive technique used to detect speci®c protein/DNA complexes. Protein levels were normalized to total nuclear protein and equivalent amounts were used in the experiments presented. The DNA element employed for the experiments was an element from the c-fos gene (hSIE) known to bind Stat1 and Stat3 homo and heterodimers with a high anity. As seen in Figure 1 , when present, a single speci®c band migrating at the expected mobility of Stat3a homodimers was observed (indicated with an arrow). All three of the high-grade and three of ®ve of the lowgrade tumors had higher levels in the complex than the normal sample from a patient with a breast metastasis (this represents residual tissue adjacent to the tumor that is removed during resection). One of the low-grade samples had a level of the complex comparable to the high-grade tumors. A faster migrating nonspeci®c (ns) complex is also shown to compare the amount of protein extract used in each lane.
To determine the identity of the protein(s) contained in the complex, a supershift experiment was performed with antibodies speci®c for the a isoforms of Stat1 and Stat3 (Figure 2 ). The addition of only the Stat3a antibody resulted in the formation of an additional complex, indicating the presence of Stat3a in the binding complex (Figure 2 ) (3-L, 9H and 10H correspond to lanes 4, 9 and 10 of Figure 1 ). Nuclear extracts from COS-7 cells transfected with a plasmid encoding Stat3a were included to indicate the relative Figure 1 Constitutive DNA binding activity in high-grade glioma. Nuclear extracts were prepared from human brain or tumor tissue and used in EMSA experiments with the high-anity Stat-binding site from the c-fos promoter (hSIE). Tumor grade is indicated. The arrow designates the speci®c Stat complex that migrates at the position of a Stat3a homodimer. (ns) indicates a nonspeci®c band that allows a convenient assessment of loading equivalency. The experiment was performed three times with similar results Figure 2 Stat3a is constitutively activated in glioma. Cell extracts were incubated with the antibodies indicated to identify the bound proteins. COS-7 cells transfected with Stat3a expression plasmid served as a control for mobility and antibody speci®city (a light exposure of the same region of the gel is also presented). Complexes ± A, ± B and ± C are denoted and represent Stat3a homodimers, Stat1/Stat3a heterodimers, and Stat1 homodimers, respectively. SS indicates a supershifted complex. The experiment was performed three times with similar results mobility of complexes formed by homodimers of Stat3a and those supershifted by the Stat3 antibody (complex A and SS, respectively). To verify this result with an independent method of detecting activated Stat3a, we analysed extracts prepared from additional tumors with an antibody speci®c for the tyrosinephosphorylated form of Stat3 (tyrosine-705). As seen in Figure 3 , in a majority of the tumors there was measurable tyrosine-phosphorylated Stat3 protein in both the low-and high-grade panel of tumors. Although Stat3 is not activated in all of the tumors, it is expressed in all but one tumor and in both of the normal brain controls (lower panels of A and B) as assessed by immunoblotting with a Stat3-speci®c monoclonal antibody. In all of the tumors at least one additional species of Stat3 with a faster mobility than Stat3a is seen, which are most likely degradation products since they are not recognized by a Stat3b antibody (data not shown).
We performed similar experiments with a panel of nuclear extracts prepared from eight medulloblastoma tumors. The extracts were immunoblotted with the phosphotyrosine-speci®c Stat3 antibody. The blots were then reblotted with a Stat3-speci®c monoclonal antibody. As seen with the glioma tumor extracts, those from all but one of the medulloblastoma tumors also had activated Stat3a (Figure 4 ). In this experiment, a low level activated Stat3 was also observed in the normal brain control sample, although the level was, in general, lower than that of the tumor samples when corrected for total protein. We conclude from this series of experiments that medulloblastoma and glioma tumor tissue samples contain signi®cantly higher levels of constitutively activated Stat3a protein compared to normal brain tissue. Thus brain tumors can be added to the growing list of neoplastic cells in which`constitutively' activated Stat3a has been detected.`A ctivated' tyrosine-phosphorylated Stat3a localizes predominantly to the tumor endothelial cells
Having demonstrated that cell extracts from glioma contain constitutively activated Stat3 protein we next wanted to localize the activated Stat3 protein in tumor tissue sections. Paran sections were obtained from several of the glioma tumors that were found to have constitutively activated Stat3a in the experiments described above. We stained the sections using the antibody speci®c for the tyrosine-phosphorylated form of Stat3 (tyrosine 705). When activated Stat3a was detected, it was most prominent in the tumor endothelial cells. Some representative examples are shown in Figure  5A (panels A ± C) and B (panels A and B). Two controls were included to demonstrate speci®city of the staining. In A serial sections were incubated with the primary antibody that was preincubated with the phosphopeptide used to generate the antibody (panels D ± F). In B serial sections in which the primary antibody was excluded (panels C and D are shown). In both instances, the signal was eliminated or greatly reduced demonstrating the speci®city of the antibody staining. We conclude that the activated Stat3a seen in glioma tumor extracts appears to be primarily due to expression in the tumor endothelial cells.
Glioma tumors express VEGF receptor 2 (VEGFR-2) and it is tyrosine phosphorylated (activated)
Noting the report that cells that express both Stat3a and the VEGFR-2 receptor result in the activation of Stat3a DNA binding activity (Korpelainen et al., 1999) , we reasoned that this receptor could be a logical candidate for the kinase responsible for the activated Stat3a seen in glial-derived tumors. Two prior studies have demonstrated that endothelial receptor tyrosine kinases are expressed in brain tumors (Hatva et al., 1995; Pietsch, 1997) . A more recent study using a receptor-speci®c phosphotyrosine antibody to assess the status of`activated' receptor in fresh astrocytic neoplastic surgical samples has shown that VEGFR-2 is speci®cally phosphorylated in the majority of anaplastic astrocytomas and glioblastoma multiforme tumors (Carroll et al., 1999) . To assess if VEGFR-2 is expressed in the tumors used in these studies, we performed immunoblot analysis on whole cell extracts from tumors using VEGFR-2 antibody ( Figure 6 ). The presence of the receptor was con®rmed in most of the tumors (16 of 18) and also in the normal brain samples although level of protein in the tumors was, in many instances, more abundant. The antibody recognizes several high molecular weight proteins that are presumably due to dierent levels of glycosylation. We also assessed the phosphorylation status (i.e. activation status) of several of the tumors using a phosphotyrosine-speci®c antibody raised to one of the VEGFR-2 autophosphorylation residues. In each of the ®ve high-grade GBM tested a single species of tyrosine-phosphorylated receptor was found to be present indicating that it was activated ( Figure 7 ) consistent with the studies described above.
Coexpression of VEGFR-2 and Stat3a leads to tyrosine phosphorylation and activation of Stat3a-mediated transcriptional activation
Having shown that the majority of the glioma tumors examined that had constitutively activated Stat3a also expressed VEGFR-2, we next wanted to see if coexpression of this endothelial receptor could lead to the activation of Stat3a in non-endothelial cells. To achieve this, we transfected COS-7 cells with expression plasmids encoding VEGFR-2 and Stat3a. Immunoblot analysis was performed on nuclear extracts prepared from these cells using the phosphotyrosine-705 speci®c antibody. As seen in Figure 8B , a major tyrosine-705 phosphorylated Stat3a band was only detected in extracts from cells in which both Stat3 and VEGFR-2 were expressed. To determine whether this tyrosine-phosphorylated Stat3a leads to the activation of Stat3a transcriptional activity, additional experiments were performed which included a Stat3 reporter plasmid. In these experiments, VEGFR-2 and Stat3a expression plasmids were cotransfected with an a-2 macroglobulin chloramphenicol acetyl-transferase (CAT) reporter vector and the amount of CAT activity was determined from cell lysates. As controls for Stat3 activation, Stat3a was also cotransfected with two additional tyrosine kinases, either wild-type erbB-2 (HER-2/neu) or c-Src, expression plasmids. As seen in Figure 8A , while expression of Stat3a alone resulted in a very modest activation of the reporter plasmid, coexpression with VEGFR-2 increased the activation by approximately 17-fold. Coexpression with c-Src also resulted in transcriptional activation, consistent with our previous report (Schaefer et al., 1999) . To exclude the possibility that the activation of Stat3a was cell-type speci®c, we performed experiments in the ®broblast cell line NIH3T3 and obtained results that were consistent with those from COS-7 cells (data not shown). We conclude from these experiments that coexpression of Stat3a and the endothelial tyrosine kinase receptor VEGFR-2 can 
Activated Stat3a increases transcription from the VEGF promoter
The increased expression of the potent endothelial growth factor VEGF by hypoxia (Shweiki et al., 1992; Ijichi et al., 1995; Levey et al., 1995) has been shown to be, at least in part, due to activated src kinase (Mukhopadhyay et al., 1995a,b; Fleming et al., 1997) . Examination of the DNA sequence of the VEGF promoter revealed the presence of two elements that resemble Stat1/3 binding sites ( Figure 9A ). Having noted this, we reasoned that the Src-activation of VEGF expression might be mediated through activation of Stat3a. To test this possibility, we transiently transfected NIH3T3 ®broblasts with a reporter plasmid fused to a 2.6 kb segment of the human VEGF promoter which contains the two putative Stat elements. Plasmids expressing Stat3a or c-Src were also cotransfected alone or in combination. As seen in Figure 9B , while neither the expression of Stat3a or cSrc alone activated VEGF expression, together they resulted in a robust increase (nearly 10-fold) in transcription from the VEGF promoter.
Discussion
In this study we have shown that Stat3a is constitutively activated in a large percentage of glioma and medulloblastoma tumors. Although normally latent, activated Stat3a has been reported in a wide variety of other neoplastic cells including those from the breast (Garcia et al., 1997) , multiple myeloma (CatlettFalcone et al., 1999) , leukemia (Weber-Nordt et al., 1996; Xia et al., 1998) , squamous cell carcinoma of the head and neck (SCCHN) (Grandis et al., 2000) , mycosis fungoides (Nielson, 1999) , prostate (Ni et al., 2000) . In multiple myeloma cells, this activation of Stat3 has been shown to increase the expression of the anti-apoptotic gene bcl-XL that results in the prevention of apoptosis (Catlett-Falcone et al., 1999) .
The constitutively activated Stat3a seen in glioma is in contrast to the majority of cell lines derived from glial tumors in which Stat3 is expressed but is not activated, unless treated with a cytokine or growth factor (Schaefer et al., 2000a) . EMSA analysis with the high anity SIE binding site from the c-fos promoter that can bind either homodimers of Stat1 or Stat3 heterodimers between the two proteins showed only complexes formed by Stat3 (SIF-A complexes). The presence of Stat3a in these complexes was con®rmed by supershift analysis with a Stat3a-speci®c antibody that resulted in the formation of a complex with a slower mobility than the SIF-A complex. Immunoblot analysis with a Stat3 phosphotyrosine-speci®c antibody also showed the presence of activated Stat3a in the majority of an additional panel of GBM tumors while similar experiments with an antibody speci®c for the activated form of Stat1 detected no tyrosine 701 phosphorylated Stat1 (data not shown). Together these results demonstrate that Stat3a, but not Stat1, is constitutively activated in glioma. Activated Stat3a, detected with an antibody that recognizes tyrosine-phosphorylated Stat3a, localized predominantly to the tumor endothelial cells of glioma tumor sections. The speci®city of this interaction was demonstrated by inclusion of a phosphopeptide used to generate the antibody or the exclusion of the primary antibody both of which eliminated speci®c staining. The staining was variable and not detected in all tumors. We believe this is due to the treatment of the sample following resection. Paran sections prepared from samples that are¯ash-frozen immediately after resection have given the most consistent results. We do not know whether the general trend of signi®cantly higher levels of activated Stat3a seen in tumor samples compared to`normal' brain tissue re¯ects the higher level of vascularization (i.e. more endothelial cells) in the tumors or is the result of an increase in the steadystate level of the phosphorylated form of the protein in the tumor cells.
An earlier study has shown that the expression of VEGFR-2 in 293T cells leads to the activation of Stat3 DNA binding activity while having no eect on the DNA binding by Stat1 (Korpelainen et al., 1999) . This apparent speci®city of activation of Stat3 by VEGFR-2 is reminiscent of the exclusive activation of Stat3 seen in the glial-derived tumors. Cell extracts from nearly all of the glioma that contained constitutively activated Stat3a were found to express VEGFR-2 by immunoblot analysis. Extracts from several additional GBM tissues were also tested for the presence of VEGFR-2 phosphorylated on a speci®c tyrosine indicating that the kinase was activated. Tyrosine-phosphorylated VEGFR-2 was detected in all ®ve of the GBM tested but not in normal brain tissue. Having demonstrated this, we next tested the possibility that VEGFR-2 could be a candidate kinase responsible for the activated Stat3a seen in the glial tumors. To attempt to model cells that express both Stat3a and VEGFR-2, we cotransfected COS-7 with expression plasmids encoding Stat3a and VEGFR-2 and assessed the activation state of Stat3a by two independent means. First, cell extracts were immunoblotted with the antibody speci®c for Stat3a that is tyrosine-phosphorylated on tyrosine-705. This clearly showed that coexpression of VEGFR-2 led to the activation of Stat3a. The transcription potential of this tyrosine-phosphorylated Stat3a was also determined in similar experiments that included a reporter plasmid containing the Stat3-responsive element of the a-2 macroglobulin gene. Similar results were obtained in experiments using ®broblasts indicating the activation of Stat3 by VEGFR-2 is not limited to a particular cell type.
Although the results presented here clearly demonstrate that coexpression of VEGFR-2 leads to the activation of Stat3, the exact mechanism of this activation remains unknown. Ligand engagement of VEGFR-2 leads to the activation of a number of signaling molecules, some with intrinsic tyrosine kinase activity, including c-Src (He et al., 1999) . The cytoplasmic autophosphorylation tyrosine residues of VEGFR-2 might provide docking sites for Stat3 and c-Src bringing the two proteins in close proximity that facilitates the activation of Stat. Alternatively, since VEGFR-2 also possesses tyrosine kinase activity it may directly phosphorylate Stat3a without the need for additional proteins. It should be noted that two tyrosines located in the cytoplasmic domain of VEGFR-2 are in the context of a (YXXQ) motif seen in other receptors that recruit Stat3, including gp130 (Stahl et al., 1995) . The results presented here provide one possible mechanism by which Stat3a is activated in glioma. Whether activated Stat3a, through the disruption of the apoptosis/proliferation balance, is a causative factor in gliomagenesis is the focus of current studies.
Finally, we presented experimental evidence that increased VEGF expression by hypoxia through Src kinase activation is mediated through Stat3a, implicating a direct role for this signaling pathway in tumor angiogenesis. This result also raises the possibility of an autocrine loop of VEGF activation that involves Stat3a signaling. Activation of Stat3a by Src or RTKs such as VEGFR-2 could lead to increased levels of VEGF which, in turn, results in sustained activation of Src/RTK through direct binding to the receptor. We are currently analysing the VEGF promoter in greater detail to further de®ne the role of Stat3a and other transcription factors in VEGF expression in endothelial and glioma-derived tumor cells.
Materials and methods

Tumor cell extracts
Residual tumor tissue was snap-frozen in liquid nitrogen. The frozen tissue was pulverized with a mortar and pestle. Nuclear extracts were prepared as described previously (Schaefer et al., 2000b) . Electrophoretic mobility shift experiments were performed using the high anity sisinducible element (hSIE) from the c-fos gene. In experiments designed to determine the identity of the proteins forming speci®c DNA binding complexes a Stat3a-speci®c antibody was included in the reaction mixture. This mixture was incubated with the protein extract for 1 h at room temperature prior to the addition of the DNA probe.
Plasmid vectors
The a-2 macroglobulin reporter plasmid, and Stat3a and cSrc expression plasmids have been described elsewhere (Schaefer et al., 1995 (Schaefer et al., , 1997 . The VEGFR-2 expression plasmid was kindly provided by B Terman (Albert Einstein College of Medicine). The wild-type erbB-2 expression plasmid was provided by D Yu (M.D. Anderson Cancer Center), the VEGF-reporter plasmid was obtained from V Sukhatme (Beth Israel Hospital) and the a-2 macroglobulin luciferase reporter was obtained from J Richards (Baylor College of Medicine).
Transient transfections and transcriptional activation experiments
COS-7 cells or NIH3T3 were transfected by calcium phosphate (Gorman et al., 1982) or by Fugene-6 (Boehringer Mannheim) following the instructions of the manufacturer. Transient transfection results were similar with cells grown in medium containing 10 or 0.5% serum. Chloramphenicol acetyl transferase assays have been described in detail previously (Schaefer et al., 2000a) .
Immunoblot analysis
Protein extracts were separated on 7 ± 10% SDS-acrylamide gels and transferred to nitrocellulose. The Stat3a tyrosinespeci®c antibody was obtained from NEB (Beverly, MA, USA). The N-terminal Stat3 monoclonal antibody was obtained from Transduction Laboratories (Lexington, KY, USA). The VEGFR-2 antibody was purchased from Santa Cruz (sc-504) (Santa Cruz, CA, USA). The VEGFR-2 phosphotyrosine-speci®c antibody (tyrosine 996) was obtained from Cell Signaling (2474) (Beverly, MA, USA).
Immunohistochemical staining of tumor sections
Sections were deparanized with xylene followed by 100% ethanol, 95% ethanol, 80% ethonal, 70% ethanol, and PBS. They were then boiled in Antigen Unmasking Solution (Vector Laboratories (H-3300) Burlingame, CA, USA) by microwaving for approximately 5 min stopping periodically to add additional solution. Endogenous peroxidase activity was then blocked by incubation in 3% hydrogen peroxide in PBS for 30 min. A Vector Laboratories ABC kit was then used according to the instructions provided. The Stat3 phospho-speci®c antibody was used at 1/200 to 1/400 dilutions. The primary antibody was incubated with the sections for 16 h at 48C in a humidi®ed atmosphere. Where indicated, a Stat3-derived phosphopeptide was incubated with the antibody for 1 h before addition to the sections. This peptide was kindly provided by Nicole Stark (NEB). For an additional control for speci®city, the primary antibody was omitted and the sections were processed using the standard protocol.
